Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.

Infante JR, Keedy VL, Jones SF, Zamboni WC, Chan E, Bendell JC, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg ML, Burris HA
Cancer Chemother Pharmacol. 2012 70 (5): 699-705

PMID: 22941375 · DOI:10.1007/s00280-012-1960-5

MeSH Terms (16)

Adult Aged Antineoplastic Agents, Phytogenic Camptothecin Dose-Response Relationship, Drug Female Glucuronosyltransferase Humans Irinotecan Liposomes Male Maximum Tolerated Dose Middle Aged Neoplasms Polyethylene Glycols Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: